National Veterinary Vaccines Company

| Learn about investment opportunities

National Veterinary Vaccines Company


The company, established in late 2019, aims to contribute to the demand in Arab countries for essential, commonly used vaccines, such as those for livestock foot-and mouth disease, bird flu and Newcastle disease, among others.


Free Zone Port of Sohar-Sultanate of Oman

Contact address
  • Icon Ghala, Bousher, Muscat Governorate
    (+968) 993 12289
  • Icon ali.alsahmy@nvvco.com
  • Icon P.O. Box61, Zip code: 134
Designed capacity

The project will be implemented in two phases:

  • – Phase I: targeting the aseptic filling and production of 114.5 million doses of different vaccines over an expansion plan period of five years
  • – Phase II: production of 144 million doses of different vaccines from year 5 onward

Capital and shareholders

The Initial capital is OMR 200 thousand, and shareholders are:

  • – AAAID: 50%
  • – Oman Food Investment Holding Company (SAOC): 50%

  • Oman Food Investment Holding Company (SAOC)

Average sales

The company's estimated sales at stability year (the tenth year of production) are estimated at USD 52.7 million

Market share

The market share is estimated at 12%.

Company products

- Foot Mouth Disease (FMD) vaccine
- Newcastle vaccine, bird flu vaccine, and others

Investment cost

The total investment cost is estimated at USD 55.4 million, representing an investment cost of USD 17.36 million at phase I and USD 38.04 million at phase II in addition to initial working capital estimated at USD 2.55 million.

Financial indicators

  • IRR: 19%
  • Payback period: 5 years and 3 months

Required finance

- Phase I: 50% equity and 50% loans
- Phase II: 32% equity, 64% loans, and 4% internal finance

Learn about the investment opportunities in:National Veterinary Vaccines Company


Participation in equity and/or Provision of loans to complete implementation of project components